Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | AGER | Q15109 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775371 | 1.00 | CYP1A2 (0.51) | CYP1A2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5775377 | 1.00 | CYP1A2 (0.51) | CYP1A2ALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL5774193 | 0.84 | PGR (0.43) | ALDH1A1TSHR | |
| SCHEMBL5774187 | 0.84 | PGR (0.43) | ALDH1A1TSHR | |
| SCHEMBL5777217 | 0.84 | PGR (0.43) | ALDH1A1TSHR | |
| SCHEMBL13563364 | 0.84 | ALDH1A1 (0.42) | CYP1A2ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL7059480 | 0.81 | TSHR (0.40) | ALDH1A1TSHRNPC1LMNASMN1; SMN2 | |
| SCHEMBL7060173 | 0.81 | TSHR (0.40) | ALDH1A1TSHRNPC1LMNASMN1; SMN2 | |
| SCHEMBL7059484 | 0.81 | TSHR (0.40) | ALDH1A1TSHRNPC1LMNASMN1; SMN2 | |
| SCHEMBL13563352 | 0.81 | BRD4 (0.44) | ALDH1A1MEN1KMT2ATSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322621-B1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1322621-A1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6586435-B2 | Useful in treatment of anxiety disorders, affective disorders such as depression, psychosis and schizophrenia, Parkinson's disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-01 | — | — | US | disclosed |
| US-20020103208-A1 | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors | BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA) (PL) | 2002-08-01 | — | — | US | disclosed |
| WO-2002024662-A1 | NEW BENZIMIDAZOLONE DERIVATIVES DISPLAYING AFFINITY AT THE SEROTONIN AND DOPAMINE RECEPTORS | BOEHRINGER INGELHEIM PHARMA GMBH & KO. KG (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103208-A1 | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors | OPRM1, HTR2C, HTR1D | CYP1A2 517/4885ALDH1A1 385/4885MEN1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.